Tissue Repair Research
TB-500 (Thymosin Beta-4 Fragment)
BioHarmony verdict
Strong recommend
TB-500 is a synthetic LKKTETQ fragment marketed for soft-tissue repair, but most human evidence is on full-length topical thymosin beta-4: Sosne 2023 reported corneal healing in 6 of 10 RGN-259 subjects versus 1 of 8 placebo.
Read full reportWhat is TB-500 (Thymosin Beta-4 Fragment)?
TB-500 is the peptide-market name for a synthetic fragment commonly described as Ac-LKKTETQ, derived from the broader biology of thymosin beta-4. Most published human and animal literature is not on TB-500 itself. It is on full-length Tbeta4, a 43-amino-acid protein involved in actin dynamics, cell migration, angiogenesis, inflammation resolution, and tissue repair.
From the BioHarmony report, reviewed 2026-09-08.
How it is thought to work
G-actin monomer binding, cell migration support, angiogenesis signaling, inflammation modulation, matrix remodeling.
Safety watch-outs
- Injection-site infection
- Rapidly worsening swelling or pain
Full risk profile in the BioHarmony report.
Dosing as published
No approved-label or study protocol is recorded for TB-500 (Thymosin Beta-4 Fragment) yet.
More reported protocols
MembersMembers can compare additional reported doses, schedules, and preparation notes.
Educator coverage (8)
Attributed viewpoints, separate from primary research.
- Stem Cells, Peptides, and the Real Reason You're Getting OldDr. Adeel Khan · 2026-05-26
- Fixing Biology: Mitochondria, GLP-1, EMFs & the Future of Human PerformanceAlex Kikel · 2026-03-04
- My Top Peptide Stack for Mental Clarity & Muscle RepairAlex Kikel · 2025-07-08
- Everything You Need To Know About Anti-Aging, Muscle Gain, Fat Loss & Recovery PeptidesBen Greenfield · 2019-04-13
- The TB-500 Masterclass | The Complete User's Guide (2026)Hunter Williams · 2026-06-17
- TB-500 Capsules vs Injection: Which Method Works Better?Jay Campbell · 2026-06-12
- Peptides for Anti Aging & InjuryJean-François Tremblay · 2018-09-22
- BPC157: The One Stop Peptide for Body, Brain & Gut with Jean Francois TremblayNathalie Niddam · 2021-02-04
Trust & sourcing
FDA identifies immunogenicity and peptide-impurity concerns for compounded TB-500 and says it has not identified human exposure data for the fragment.
Primary sources
- Certain bulk drug substances for use in compounding that may present significant safety risksU.S. Food and Drug Administration · 2026-04-22
Related peptides for recovery & tissue repair
Free guide
The Ultimate Peptides Guide
Spot stronger candidates, weak evidence, and seller red flags before you buy.